Rocuronium Bromide (Rocuronium Bromide) Patent Expiration, LOE Window & CMS Spending
Rocuronium Bromide (Rocuronium Bromide) by Fresenius Kabi: FDA Orange Book LOE 2039-07-22, 21 AB generics, $30.3M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | N217472 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2039-07-22 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 21 |
| 2024 CMS Total Public Spend | $30.3M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $30.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.